Cargando…
Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
Metastatic melanomas in the pediatric population are rare, but they have been appearing more frequently. Unfortunately, little is known about the differences in the biology and therapeutic implications of pediatric metastatic melanomas when compared to those found in adults. Herein, we have presente...
Autores principales: | Bernal Vaca, Laura, Mendoza, Sara D, Vergel, Juan C, Rueda, Xavier, Bruges, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414191/ https://www.ncbi.nlm.nih.gov/pubmed/30899610 http://dx.doi.org/10.7759/cureus.3859 |
Ejemplares similares
-
PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022) -
Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021) -
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021) -
Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017) -
Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)